molnupiravir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5377 | None |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
EIDD-1931 has broad spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to the nucleoside analog inhibitor remdesivir
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 24, 2021 | PMDA | MSD K.K. |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Product use issue | 94.09 | 64.35 | 33 | 226 | 149442 | 50455423 |
| Product use complaint | 88.95 | 64.35 | 14 | 245 | 1788 | 50603077 |
| Wrong technique in product usage process | 74.91 | 64.35 | 22 | 237 | 55488 | 50549377 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| COVID-19 | 120.10 | 65.34 | 33 | 248 | 35981 | 29538265 |
| Product use issue | 70.96 | 65.34 | 24 | 257 | 51420 | 29522826 |
| Accidental underdose | 69.11 | 65.34 | 10 | 271 | 383 | 29573863 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Product use issue | 164.24 | 64.64 | 58 | 517 | 151657 | 64346500 |
| COVID-19 | 153.10 | 64.64 | 45 | 530 | 65095 | 64433062 |
| Accidental underdose | 134.79 | 64.64 | 19 | 556 | 643 | 64497514 |
| Product use complaint | 117.49 | 64.64 | 19 | 556 | 1627 | 64496530 |
| Wrong technique in product usage process | 101.92 | 64.64 | 33 | 542 | 64941 | 64433216 |
| Underdose | 78.96 | 64.64 | 22 | 553 | 25807 | 64472350 |
| No adverse event | 76.77 | 64.64 | 22 | 553 | 28539 | 64469618 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| CHEBI has role | CHEBI:36044 | antiviral drugs |
| CHEBI has role | CHEBI:50266 | Prodrugs |
| CHEBI has role | CHEBI:149553 | anticoronaviral drug |
| CHEBI has role | CHEBI:22587 | antiviral agents |
| CHEBI has role | CHEBI:49103 | drug metabolites |
| CHEBI has role | CHEBI:76967 | human xenobiotic metabolites |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| COVID-19 | indication | 840539006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.55 | acidic |
| pKa2 | 11.55 | acidic |
| pKa3 | 13.03 | acidic |
| pKa4 | 4.03 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| YA84KI1VEW | UNII |
| C5435024 | UMLSCUI |
| CHEBI:180653 | CHEBI |
| CHEBI:51369 | CHEBI |
| CHEMBL4650320 | ChEMBL_ID |
| 145996610 | PUBCHEM_CID |
| DB15661 | DRUGBANK_ID |
| C010737 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10737 | IUPHAR_LIGAND_ID |
| DB15660 | DRUGBANK_ID |
| 2587901 | RXNORM |
| 354402 | MMSL |
| 40179 | MMSL |
| d09837 | MMSL |
| 4041077 | VANDF |
| 197020 | PUBCHEM_CID |
| C0067182 | UMLSCUI |
| D11943 | KEGG_DRUG |
| 018901 | NDDF |
| C000656703 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11853 | INN_ID |
| 2492423-29-5 | SECONDARY_CAS_RN |
| 3258-02-4 | SECONDARY_CAS_RN |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| molnupiravir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-5055 | CAPSULE | 200 mg | ORAL | Emergency Use Authorization | 31 sections |
| molnupiravir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-5055 | CAPSULE | 200 mg | ORAL | Emergency Use Authorization | 31 sections |